Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder. - sprookjes - yvandenbroek - TriplyDB

Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.

Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.

http://www.wikidata.org/entity/Q37397705

about

Adrenal activity and metabolic risk during randomized escitalopram or placebo treatment in PCOS.

P2860

Q51246676-EA9A100F-A5F6-44D3-87A7-17944B8380F1

P2860

Metabolic Abnormalities Related to Treatment With Selective Serotonin Reuptake Inhibitors in Patients With Schizophrenia or Bipolar Disorder.

http://www.wikidata.org/entity/Q37397705

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Metabolic Abnormalities Relate ...... zophrenia or Bipolar Disorder.

@en

Metabolic Abnormalities Relate ...... zophrenia or Bipolar Disorder.

@nl

type

label

Metabolic Abnormalities Relate ...... zophrenia or Bipolar Disorder.

@en

Metabolic Abnormalities Relate ...... zophrenia or Bipolar Disorder.

@nl

prefLabel

Metabolic Abnormalities Relate ...... zophrenia or Bipolar Disorder.

@en

Metabolic Abnormalities Relate ...... zophrenia or Bipolar Disorder.

@nl

P1433

Q37397705-560735E6-9C29-4A47-ABF2-1D9C57660A79

P1476

Q37397705-E265F434-3695-4D84-9999-1BCD971469F3

P2093

Q37397705-61E4EA66-4E80-48A6-919E-445D169F2E06

Q37397705-628B7D56-9A77-4CCD-A3EC-FE690983F667

Q37397705-CFCC6093-9622-4E52-B644-73EF26824BC6

Q37397705-E7BAD9F0-0EC4-48D8-9BF0-4493A9C47461

Q37397705-F88AEE61-0F57-4E2D-A877-1A4A77FF381E

P2860

Q37397705-1485377D-9830-4889-B47D-9711314E3B6E

Q37397705-1EE0AA83-673E-4DDA-B07B-DE3E43572875

Q37397705-22330CC1-5F2F-463C-8F7E-B1E0E133F6BA

Q37397705-2385BEE5-5FF9-440D-82DD-6BFC0667BA43

Q37397705-32027E4E-98D0-4949-AC2C-4764A48BA0DD

Q37397705-3BDF8750-4BD2-42D2-AAA5-D844D6C11D21

Q37397705-405EFB7B-115E-435E-8E31-8E649EE54703

Q37397705-62DB5EF1-6A5A-4CEF-9E26-AD670823FFBB

Q37397705-71352DE8-9700-4323-88D6-F1901A2C0CCE

Q37397705-78FA200C-4FF7-411B-8E57-2817750221BB

P304

Q37397705-84739514-D3CA-4E7C-B202-A608C104133F

P31

Q37397705-2898404F-F4D2-4929-804F-0A6AA09E873D

P356

Q37397705-49CD4558-475A-4E01-BEA9-7578A883D1AF

P407

Q37397705-CCCAEF40-A9DA-4B6B-A4BE-5C35C982B93E

P433

Q37397705-D0667AA0-205B-4B18-AF42-800CB960956C

P478

Q37397705-48875035-A0C1-4647-8E40-979B4AF2F7A3

P50

Q37397705-8B28B0E2-9312-4A5C-8F68-A2DFC4E674DA

Q37397705-9E204442-B96F-42C9-B5DF-AC53E8B7AB93

P577

Q37397705-610DC848-DAED-489A-BEE3-79CF5B1989DA

P698

Q37397705-84A0CC90-B9AD-4F8E-AAE3-9E1B7AB4D33F

P921

Q37397705-0AE18472-F0D6-4416-81F3-957E8349737C

Q37397705-D5DB42C7-3E9C-44C6-B03F-13402FA58B1A

Q37397705-a6a711fa-f62c-482c-8694-25a47288ae76

P932

Q37397705-C306F0DB-E00C-4E94-A90E-CB5D2F4F359B

P356

JCP.0000000000000582

P1433

Journal of Clinical Psychopharmacology

P1476

Metabolic Abnormalities Relate ...... zophrenia or Bipolar Disorder.

@en

P2093

Anne Engum

http://www.w3.org/2001/XMLSchema#string

Ingrid Dieset

http://www.w3.org/2001/XMLSchema#string

Katrine Kveli Fjukstad

http://www.w3.org/2001/XMLSchema#string

Nils Eiel Steen

http://www.w3.org/2001/XMLSchema#string

Stian Lydersen

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

Comparison of methods for imputing limited-range variables: a simulation study.

Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.

Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.

Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors.

Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.

Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.

Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study.

P304

615-620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JCP.0000000000000582

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Ole A. Andreassen

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27749681

http://www.w3.org/2001/XMLSchema#string

P921

bipolar disorder

P932

5098465

http://www.w3.org/2001/XMLSchema#string